Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study

• Status: Not yet recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This phase II trials studies the impact of total intravenous anesthesia (TIVA) following cancer surgery. Surgery and the anesthesia delivered causes physiologic stress and trauma resulting in immune suppression. TIVA is an alternative method of general anesthesia that has several benefits over volatile inhalation agents such as reducing nausea, vomiting, and opioid consumption, and promotes earlier return of bowel function following surgery. In addition, TIVA is less immunosuppressive than inhalational agents and has been shown to decrease cancer cell proliferation, migration, and metastasis formation. Giving TIVA during cancer-directed abdominal surgery may decrease the immunosuppressive state in the peri-surgical period.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ohio State University Comprehensive Cancer Center
• Treatments: Anesthetics

Criteria

Inclusion Criteria:

• Adults: >= 18 years

• Diagnosed with pancreatic adenocarcinoma

• Presented for surgery between January 1, 2021 and December 31, 2023

• Able to provide consent

Exclusion Criteria:

• Allergies to study anesthetic - intravenous Propofol, or a history of malignant hyperthermia to volatile inhaled anesthetics

• Prisoner status